BWX Technologies Signals Strong Growth in Earnings Call

Bwx Technologies Inc ((BWXT)) has held its Q4 earnings call. Read on for the main highlights of the call.

BWX Technologies’ latest earnings call struck an upbeat tone, with management leaning heavily into strong 2025 performance and an even brighter 2026 outlook. Executives acknowledged some near‑term margin and regulatory headwinds, yet emphasized surging backlog, accelerating commercial growth, and ample liquidity as the dominant forces shaping a positive multi‑year story.

Full-Year Financial Outperformance

BWX Technologies closed 2025 ahead of its own targets, underscoring solid execution across the portfolio. Revenue climbed 18%, adjusted EBITDA rose 15%, earnings per share jumped 20%, and free cash flow advanced 16%, all surpassing initial guidance and giving investors confidence in the company’s operating leverage.

Backlog Expansion Underpins Visibility

The company’s order book expanded sharply, reinforcing multi‑year revenue visibility that many industrial investors prize. Total backlog ended 2025 at $7.3 billion, up 50% year over year, while commercial backlog reached $1.7 billion, up 85% annually and 16% sequentially, signaling durable demand in key growth markets.

Robust Quarterly Performance

Fourth‑quarter results added momentum to the full‑year narrative, with broad‑based growth and improving profitability. Revenue rose 19% to $886 million, including 4% organic growth, while adjusted EBITDA increased 13% to $148 million and adjusted EPS advanced 17% to $1.08.

Commercial Operations Momentum

Commercial operations were a standout, showcasing how BWXT is capitalizing on the nuclear and services upcycle. Segment revenue surged 95% in the quarter, including 31% organic growth, with adjusted EBITDA up 87% to $44 million and margins improving to 14.9%, and commercial nuclear power posted a book‑to‑bill above 2.

Medical Business Reaches New Scale

BWXT Medical delivered a key milestone that strengthens the company’s healthcare credentials and recurring revenue base. The unit generated slightly more than $100 million of annual revenue, up about 20% year over year, driven by double‑digit diagnostic isotope growth, higher actinium sales, and stable TheraSphere performance.

Strategic Acquisitions and Major Awards

Recent deals are already translating into notable contract wins and expanded capabilities across the nuclear value chain. The AOT and Kinectrics acquisitions helped secure a $1.6 billion high‑purity depleted uranium contract and the owner’s engineer role for the Kozloduy AP1000 project, while Kinectrics boosts international technical services and licensing reach.

Operational and Strategic Investments

Management highlighted an aggressive build‑out of infrastructure aimed at supporting long‑term nuclear and defense growth. The company opened the BWST Innovation Campus, completed a centrifuge manufacturing development facility in seven months, launched a new digital center, advanced HPDU manufacturing design, and continued expanding its Cambridge plant.

Balance Sheet and Liquidity Strength

BWXT has fortified its financial flexibility, giving it ample room to fund growth and weather volatility. The company closed a $1.25 billion 0% coupon convertible offering with an elevated conversion price, refinanced credit facilities at a lower cost of debt, and finished the year with roughly $1.7 billion in liquidity.

Key Delivery and Product Wins

Execution on major defense and advanced nuclear programs remains a critical part of the BWXT story. The company shipped two large steam generators for CVN 81 and delivered the first TRISO fuel core for Project Pele to Idaho National Lab, while continuing TRISO manufacturing for Antares toward a targeted July 4 reactor criticality.

Government Operations Near-Term Pressure

Not all segments are firing at peak profitability, and management was candid about short‑term headwinds. Government Operations revenue slipped 1% in the quarter and adjusted EBITDA fell 5%, with margins easing to 18.8%, and the company expects slightly lower government margins in 2026 as new programs ramp at initially reduced profitability.

Margin and Mix Headwinds From New Programs

New defense fuels and HPDU contracts are strategically important but weigh on near‑term margins as capacity comes online. These programs require upfront infrastructure investment and begin with lower initial margins, leading management to forecast a back‑half‑weighted 2026 and only flat to slightly higher EBITDA and EPS in the first quarter.

Tech 99 Regulatory and Quality Uncertainty

The company’s medical pipeline carries upside but also regulatory and technical risk that management is unwilling to bake into near‑term numbers. Tech 99 has not yet been submitted to regulators and is dealing with filtration and concentration challenges, so no Tech 99 revenue is included in 2026 guidance, leaving it as a potential later‑stage catalyst.

Lower-Margin Early-Stage Programs

Several high‑profile initiatives are still in the early phases of contract negotiation and execution, tempering short‑term profitability. Defense fuels and HPDU work currently contribute lower‑margin activity as infrastructure and capacity ramps, which management framed as an investment phase ahead of expected margin improvement over time.

Regulatory Overhang on Kinectrics Deal

BWXT also faces a degree of deal‑related uncertainty that investors will watch closely. The Kinectrics acquisition remains under review by the Canadian Competition Bureau with no new updates, creating a potential timing risk even as the company underscores the strategic value of the asset.

Digital Initiatives and Security Constraints

The company’s push into AI and digital transformation is real but necessarily slower in its most sensitive operations. Management noted that classified manufacturing environments impose restrictions on connectivity and require strict security clearances, factors that could moderate the pace of digital deployment in government‑focused facilities.

Forward-Looking Guidance and Outlook

For 2026, BWXT guided to revenue of about $3.75 billion, up in the high teens, with adjusted EBITDA of $645–$660 million and non‑GAAP EPS of $4.55–$4.70, implying mid‑ to high‑teens earnings growth. Free cash flow is expected at $305–$320 million, backed by a $7.3 billion backlog, strong commercial growth of roughly 25%, and a back‑half‑weighted year as new programs mature.

BWX Technologies’ earnings call painted a picture of a company investing through short‑term margin pressure to capture long‑duration nuclear and defense growth. Strong 2025 results, a rapidly growing backlog, and disciplined balance‑sheet management underpin a constructive outlook, though investors will track execution on new programs, medical development, and regulatory reviews closely.